Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
前收盘价
US$5.68
−US$0.12 · -2.07%
盘中时间采用ET。市场数据可能有所延迟。
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
日内区间
当前US$5.68
52周区间
当前US$5.68
盘中时间采用ET。市场数据可能有所延迟。
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
日内区间
当前US$5.68
52周区间
当前US$5.68
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 5087 USD | 2万 USD | 5281.5 USD | 373.4万 USD | 16.69万 USD |
| 毛利 | −5087 USD | −2万 USD | −5281.5 USD | −373.4万 USD | −16.69万 USD |
| 研究与开发 | 1842.6万 USD | 1365.88万 USD | 664.63万 USD | 373.4万 USD | 200.36万 USD |
| 销售、一般及管理费用 | 743.8万 USD | 516.24万 USD | 456.73万 USD | 469.4万 USD | 262.43万 USD |
| 营业费用 | 2645.9万 USD | 1937.58万 USD | 1165.61万 USD | 469.4万 USD | 462.79万 USD |
| 利息收入 | 136万 USD | 95.53万 USD | 100.48万 USD | 6.3万 USD | 6263 USD |
| 利息支出 | — | — | 13.34万 USD | — | 77.28万 USD |
| 折旧和摊销 | 4000 USD | 1.39万 USD | 5276 USD | 31.97万 USD | 16.2万 USD |
| 营业利润 | −2645.9万 USD | −1937.58万 USD | −1165.61万 USD | −842.8万 USD | −664.79万 USD |
| 净利润 | −2487.3万 USD | −1957.86万 USD | −1197.72万 USD | −1132.2万 USD | −1550.57万 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$20.00
上涨空间 252.11%AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。